Page last updated: 2024-08-24

antineoplaston a10 and Hypercholesterolemia

antineoplaston a10 has been researched along with Hypercholesterolemia in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Cho, JM; Choi, JY; Chun, SW; Chung, JW; Hong, SJ; Hong, YJ; Kim, BJ; Kim, CS; Kim, DH; Kim, HS; Kim, KS; Kim, SH; Kim, TN; Lee, CW; Lee, SA; Lee, SH; Lee, SR; Park, HC; Sung, JH; Yoon, SB	1

Trials

1 trial(s) available for antineoplaston a10 and Hypercholesterolemia

Article	Year
Effectiveness of low-intensity atorvastatin 5 mg and ezetimibe 10 mg combination therapy compared with moderate-intensity atorvastatin 10 mg monotherapy: A randomized, double-blinded, multi-center, phase III study. Medicine, 2023, Nov-24, Volume: 102, Issue:47 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Treatment Outcome	2023

Article

Year

Effectiveness of low-intensity atorvastatin 5 mg and ezetimibe 10 mg combination therapy compared with moderate-intensity atorvastatin 10 mg monotherapy: A randomized, double-blinded, multi-center, phase III study.

Medicine, 2023, Nov-24, Volume: 102, Issue:47

Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Treatment Outcome

2023